These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18396752)

  • 21. Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae.
    Karlas T; Wiegand J; Berg T
    Best Pract Res Clin Endocrinol Metab; 2013 Apr; 27(2):195-208. PubMed ID: 23731881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The central role of the non alcoholic fatty liver disease in metabolic syndrome.
    Hurjui DM; Niţă O; Graur LI; Mihalache L; Popescu DS; Graur M
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):425-31. PubMed ID: 23077931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent concepts in non-alcoholic fatty liver disease.
    Adams LA; Angulo P
    Diabet Med; 2005 Sep; 22(9):1129-33. PubMed ID: 16108837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonalcoholic fatty liver disease: the hepatic metabolic syndrome.
    Page J
    J Am Acad Nurse Pract; 2012 Jun; 24(6):345-51. PubMed ID: 22672485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The epidemiology of nonalcoholic fatty liver disease in adults.
    Clark JM
    J Clin Gastroenterol; 2006 Mar; 40 Suppl 1():S5-10. PubMed ID: 16540768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonalcoholic fatty liver disease and the metabolic syndrome.
    Marchesini G; Babini M
    Minerva Cardioangiol; 2006 Apr; 54(2):229-39. PubMed ID: 16778754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Weight loss as a treatment for nonalcoholic fatty liver disease.
    Clark JM
    J Clin Gastroenterol; 2006 Mar; 40 Suppl 1():S39-43. PubMed ID: 16540766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.
    Marchesini G; Bugianesi E; Forlani G; Cerrelli F; Lenzi M; Manini R; Natale S; Vanni E; Villanova N; Melchionda N; Rizzetto M
    Hepatology; 2003 Apr; 37(4):917-23. PubMed ID: 12668987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of diet and nutrient composition in nonalcoholic Fatty liver disease.
    McCarthy EM; Rinella ME
    J Acad Nutr Diet; 2012 Mar; 112(3):401-9. PubMed ID: 22717200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathology of nonalcoholic fatty liver disease.
    Yeh MM; Brunt EM
    Am J Clin Pathol; 2007 Nov; 128(5):837-47. PubMed ID: 17951208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?
    Fan JG; Saibara T; Chitturi S; Kim BI; Sung JJ; Chutaputti A;
    J Gastroenterol Hepatol; 2007 Jun; 22(6):794-800. PubMed ID: 17498218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT).
    Kalra S; Vithalani M; Gulati G; Kulkarni CM; Kadam Y; Pallivathukkal J; Das B; Sahay R; Modi KD
    J Assoc Physicians India; 2013 Jul; 61(7):448-53. PubMed ID: 24772746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treating the metabolic syndrome.
    Bianchi C; Penno G; Romero F; Del Prato S; Miccoli R
    Expert Rev Cardiovasc Ther; 2007 May; 5(3):491-506. PubMed ID: 17489673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonalcoholic fatty liver disease in India--is it different?
    Duseja A
    Trop Gastroenterol; 2006; 27(4):142-6. PubMed ID: 17542290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome.
    Yki-Järvinen H
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):901-10. PubMed ID: 24731669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver fat in the pathogenesis of insulin resistance and type 2 diabetes.
    Yki-Järvinen H
    Dig Dis; 2010; 28(1):203-9. PubMed ID: 20460912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonalcoholic steatohepatitis and the metabolic syndrome.
    Jiang J; Torok N
    Metab Syndr Relat Disord; 2008 Mar; 6(1):1-7. PubMed ID: 18370830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review article: the treatment of fatty liver disease associated with the metabolic syndrome.
    Marchesini G; Natale S; Manini R; Agostini F
    Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():37-9. PubMed ID: 16225470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fish oil improves lipid metabolism and ameliorates inflammation in patients with metabolic syndrome: impact of nonalcoholic fatty liver disease.
    Al-Gayyar MM; Shams ME; Barakat EA
    Pharm Biol; 2012 Mar; 50(3):297-303. PubMed ID: 22103753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.